

Retatrutide



Certificate No.
CP-QCC-2026-060906

Lot Number
RET-JUN26-9X3ONX

Release Date
2026.06.11

QUALITY CONTROL CERTIFICATE

GLP-1/GIP/Glucagon Triple Receptor Agonist (Retatrutide)

PRODUCT INFORMATION

Product Name	Retatrutide
Dosage Form	Lyophilized powder (reconstitute before use)
Peptide Content	10 mg per vial
Appearance	White to off-white lyophilized powder
Solubility	Freely soluble in sterile water or bacteriostatic water
Storage	Refrigerate 2-8 C; protect from light and moisture
Intended Use	Laboratory research use only - not for human consumption

COMPOSITION REFERENCE

Y-Aib-Q-G-T-F-T-S-D-Y-S-I-αMeL-L-D-K(γE-AEEA-C20diacid)-A-Q-Aib-A-F-I-E-Y-L-L-E-G-G-P-S-S-G-A-P-P-P-S-NH2

39-mer GIP/GLP-1/glucagon triple agonist; C20 fatty diacid at K17; C-terminal amide; confirmed by LC-MS

QUALITY CONTROL TEST RESULTS

Test	Method	Specification	Result	Status
Appearance	Visual	White lyophilized powder	Conforms	PASS
Identity	HPLC/MS	Matches reference	Confirmed	PASS
Purity	HPLC	>= 98.0%	99.1%	PASS
Peptide Content	Gravimetric	Report result	10.2 mg	PASS
Related Substances	HPLC	<= 2.0%	0.9%	PASS
Endotoxin	USP <85> LAL	< 0.50 EU/mg	< 0.10 EU/mg	PASS
Sterility	USP <71>	No growth (14 days)	No growth	PASS

CERTIFICATION

This product has been manufactured, tested, and released in accordance with national quality standards. All tests performed meet or exceed applicable specifications.

RELEASED FOR DISTRIBUTION • LOT: RET-JUN26-9X3ONX • RELEASE DATE: 2026.06.11